Current Headlines

  1. International Stem Cell Community Day In Hamburg

    On April 4, 2017 the first international Stem Cell Community Day will take place in Hamburg. Experts from academia and industry will discuss the status quo, perspectives, and challenges in stem cell cultivation for research and therapy, according to the event’s motto: “Bioprocessing Technologies in Stem Cell Research – Challenges and Chances for Commercialization”

  2. Contract Manufacturer Pfizer CentreOne Expands Fill-Finish Services To Its Kalamazoo, Michigan, Facility

    Pfizer CentreOne, a global contract manufacturing organization embedded within Pfizer, recently announced that it has expanded its fill-finish services to its Kalamazoo, Michigan (United States), site.

  3. Thermo Fisher Scientific Granted Early HSR Termination For Finesse Solutions Acquisition

    Thermo Fisher Scientific Inc. announced that its pending acquisition of Finesse Solutions, Inc., a leader in the development of scalable control automation systems and software for bioproduction, has received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

  4. Eppendorf Introduces The New BioFlo 120 Bioprocess Control Station

    Leading life science company Eppendorf introduces the BioFlo 120, their latest bench scale fermentor/bioreactor system for research and development.

  5. Outsourced Pharma Announces Boston Forum Agenda

    Outsourced Pharma is excited to announce the agenda for its Boston event. The Summit On Modern-Day Drug Development and Manufacturing Outsourcing is scheduled for April 26 and 27 at the Boston Park Plaza. The complete agenda and list of panelists can be found here (

  6. MilliporeSigma Launches First Commercial Service To Predict Multiple Sources Of DNA Damage

    MilliporeSigma has introduced CAN MultiFlow™ screening services to more accurately predict genotoxic and mode of action* properties of substances, ingredients and drug compounds. Offered through its BioReliance® testing facilities, MilliporeSigma will be the first company to provide this service in the United States.

  7. Sartorius Stedim Biotech Supports Mainstream Adoption Of Quality By Design

    Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, has developed an innovative and fully integrated technology platform to meet the requirements of today’s upstream bioprocessing. It will allow customers to adopt a Quality by Design (QbD) approach in which they build quality into their biological products by combining the power of highthroughput mini bioreactors with data analysis and knowledge management tools so that robust and well-characterized processes can be scaled up at the first attempt.

  8. MilliporeSigma Opens Production Facility Exclusively For Meglumine In Spain

    MilliporeSigma, a leading science and technology company, recently announced the opening of a facility in Mollet des Vallès, Spain dedicated to the manufacture of meglumine, an FDA-approved excipient for pharmaceuticals and a component of medical imaging contrast media.

  9. The German National Center For Tumor Diseases (NCT) Heidelberg And Protagen AG Investigate Responsiveness To Checkpoint Inhibitors In Melanoma

    The German National Center for Tumor Diseases (NCT) Heidelberg and Protagen AG recently announced a collaboration to utilize Protagen’s SeroTag technology to identify biomarkers that predict therapy responsiveness and the detection of immune-related adverse events (irAEs) in melanoma patients treated with checkpoint inhibitors

  10. Sartorius Stedim Biotech Opens New Validation Service Lab At Shanghai Site

    Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, opened a new validation service laboratory yesterday at its site in Shanghai Zhangjiang Hi-Tech Park. The opening event was attended by business partners from the biopharmaceutical industry and representatives of the local community.